New eye drop could offer relief for dry eye sufferers unhappy with restasis
NCT ID NCT07267299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether switching from Restasis to a new eye drop called acoltremon 0.003% can better relieve dry eye symptoms and improve tear production. About 100 adults with chronic dry eye who are dissatisfied with Restasis will take part. Researchers will measure changes in tear production and symptom scores over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acoltremon 0.003% eye drops
- What this could lead to
- If successful, this could offer a more effective option for people with chronic dry eye who are not satisfied with Restasis.
- What could go wrong
- This is a small, early-phase trial with only 100 participants and a short 28-day follow-up. Results may not apply to all dry eye patients, and the improvement may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can insulin eye drops quench dry eyes?
- Can a new eye drop soothe severe dry eye?
- New imaging tools put to the test for measuring dry eye treatment effects
- Could a special screen light reduce tired eyes and dryness?
- Nasal spray could make contact lenses more comfortable
- Dry eye drops may sharpen cataract surgery outcomes